N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Serum Endogenous Estrogens, Estrogen Receptors, and Sirtuin-1 and -3 After Resveratrol Supplementation

Sponsor: InCor Heart Institute • ClinicalTrials.gov ID: NCT07865377

Registry updated: 2026-10-16
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

Atherosclerotic coronary artery disease (CAD) is a leading cause of mortality among postmenopausal women. Resveratrol, a phenolic compound with antioxidant properties, may influence lipid metabolism, endothelial function, and platelet aggregation, while sirtuin-1 and sirtuin-3 regulate metabolic and hormonal responses to nutritional stimuli. This randomized, double-blind, placebo-controlled trial evaluates the effects of trans-resveratrol supplementation (1000 mg/day) versus placebo, over 90 days, on serum estradiol and estrone levels, gene expression of estrogen receptors alpha and beta, and sirtuins 1 and 3 in 80 postmenopausal women with CAD. Findings may inform therapeutic strategies for postmenopausal women with chronic coronary disease.

Interventions

  • Trans-resveratrol, 1000 mg daily for 90 days (Dietary supplement)
    Trans-resveratrol, 1000 mg daily for 90 days
  • Placebo (Other)
    Starch, 1000 mg daily for 90 days

Eligibility criteria

Inclusion Criteria: * Postmenopausal women; * Diagnosed coronary artery disease; * Stable coronary disease; Exclusion Criteria: * Hypo- or hyperthyroidism, * Rheumatic disease, * Use of alcohol, * hepatic failure, * renal failure * hormone replacement therapy * use of insulin

Conditions

Coronary Artery Disease (CAD) Menopause Hormones

Locations

  • Servico de Prevencao, Cardiopatia na Mulher e Reabilitacao Cardiovascular, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, — São Paulo, São Paulo, Brazil
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record